APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Disease Aerosol Delivery Devices

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pulmonary Disease Aerosol Delivery Devices Industry Research Report 2026

28 December 2025134 pages

Choose your research edition.

Industry ResearchPulmonary Disease Aerosol Delivery Devices Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Disease Aerosol Delivery Devices Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Pulmonary Disease Aerosol Delivery Devices Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Disease Aerosol Delivery Devices Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Disease Aerosol Delivery Devices Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Pulmonary Disease Aerosol Delivery Devices market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pulmonary Disease Aerosol Delivery Devices is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pulmonary Disease Aerosol Delivery Devices is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Pulmonary Disease Aerosol Delivery Devices is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pulmonary Disease Aerosol Delivery Devices include Novartis, Merck, Viatris, GlaxoSmithKline (GSK), AstraZeneca, Vectura, Teva Pharmaceutical Industries, PARI International and OMRON, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pulmonary Disease Aerosol Delivery Devices market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Disease Aerosol Delivery Devices Market by Company

Novartis

Merck

Viatris

GlaxoSmithKline (GSK)

AstraZeneca

Vectura

Teva Pharmaceutical Industries

PARI International

OMRON

Monaghan Medical

Koninklijke Philips

H&T Presspart

Chiesi Farmaceutici

Boehringer Ingelheim

AptarGroup

Pulmonary Disease Aerosol Delivery Devices Segment by Type

Metered- dose Inhalers

Dry-powder Inhalers

Nebulizers

Pulmonary Disease Aerosol Delivery Devices Segment by Application

Asthma

Idiopathic Pulmonary Fibrosis (IPF)

Cystic Fibrosis (CF)

Chronic Obstructive Pulmonary Disease (COPD)

Others

Pulmonary Disease Aerosol Delivery Devices Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Disease Aerosol Delivery Devices market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Disease Aerosol Delivery Devices and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Disease Aerosol Delivery Devices.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Pulmonary Disease Aerosol Delivery Devices manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Pulmonary Disease Aerosol Delivery Devices by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Pulmonary Disease Aerosol Delivery Devices in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pulmonary Disease Aerosol Delivery Devices Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Pulmonary Disease Aerosol Delivery Devices Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Manufacturers (2021-2026) Table 8. Global Pulmonary Disease Aerosol Delivery Devices Revenue of Manufacturers (2021-2026) Table 9. Global Pulmonary Disease Aerosol Delivery Devices Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Pulmonary Disease Aerosol Delivery Devices Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Pulmonary Disease Aerosol Delivery Devices Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Product Type & Application Table 14. Global Pulmonary Disease Aerosol Delivery Devices Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Pulmonary Disease Aerosol Delivery Devices by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novartis Company Information Table 19. Novartis Business Overview Table 20. Novartis Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 22. Novartis Recent Developments Table 23. Merck Company Information Table 24. Merck Business Overview Table 25. Merck Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 27. Merck Recent Developments Table 28. Viatris Company Information Table 29. Viatris Business Overview Table 30. Viatris Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 32. Viatris Recent Developments Table 33. GlaxoSmithKline (GSK) Company Information Table 34. GlaxoSmithKline (GSK) Business Overview Table 35. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 37. GlaxoSmithKline (GSK) Recent Developments Table 38. AstraZeneca Company Information Table 39. AstraZeneca Business Overview Table 40. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 42. AstraZeneca Recent Developments Table 43. Vectura Company Information Table 44. Vectura Business Overview Table 45. Vectura Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 47. Vectura Recent Developments Table 48. Teva Pharmaceutical Industries Company Information Table 49. Teva Pharmaceutical Industries Business Overview Table 50. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 52. Teva Pharmaceutical Industries Recent Developments Table 53. PARI International Company Information Table 54. PARI International Business Overview Table 55. PARI International Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 57. PARI International Recent Developments Table 58. OMRON Company Information Table 59. OMRON Business Overview Table 60. OMRON Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 62. OMRON Recent Developments Table 63. Monaghan Medical Company Information Table 64. Monaghan Medical Business Overview Table 65. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 67. Monaghan Medical Recent Developments Table 68. Koninklijke Philips Company Information Table 69. Koninklijke Philips Business Overview Table 70. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 72. Koninklijke Philips Recent Developments Table 73. H&T Presspart Company Information Table 74. H&T Presspart Business Overview Table 75. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 77. H&T Presspart Recent Developments Table 78. Chiesi Farmaceutici Company Information Table 79. Chiesi Farmaceutici Business Overview Table 80. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 82. Chiesi Farmaceutici Recent Developments Table 83. Boehringer Ingelheim Company Information Table 84. Boehringer Ingelheim Business Overview Table 85. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 87. Boehringer Ingelheim Recent Developments Table 88. AptarGroup Company Information Table 89. AptarGroup Business Overview Table 90. AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio Table 92. AptarGroup Recent Developments Table 93. Global Pulmonary Disease Aerosol Delivery Devices Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2021-2026) & (K Units) Table 95. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region (2021-2026) Table 96. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region (2027-2032) & (K Units) Table 97. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Region (2027-2032) Table 98. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region (2021-2026) Table 100. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Region (2027-2032) Table 102. North America Pulmonary Disease Aerosol Delivery Devices Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 104. North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 105. North America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 109. Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 110. Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Pulmonary Disease Aerosol Delivery Devices Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 119. South America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 120. South America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2026) & (K Units) Table 128. Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2027-2032) & (K Units) Table 129. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2026) Table 130. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2027-2032) Table 131. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2026) Table 134. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2027-2032) Table 135. Global Pulmonary Disease Aerosol Delivery Devices Price by Type (2021-2026) & (US$/Unit) Table 136. Global Pulmonary Disease Aerosol Delivery Devices Price by Type (2027-2032) & (US$/Unit) Table 137. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2026) & (K Units) Table 138. Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2027-2032) & (K Units) Table 139. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2026) Table 140. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2027-2032) Table 141. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2026) Table 144. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2027-2032) Table 145. Global Pulmonary Disease Aerosol Delivery Devices Price by Application (2021-2026) & (US$/Unit) Table 146. Global Pulmonary Disease Aerosol Delivery Devices Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Pulmonary Disease Aerosol Delivery Devices Distributors List Table 150. Pulmonary Disease Aerosol Delivery Devices Customers List Table 151. Pulmonary Disease Aerosol Delivery Devices Industry Trends Table 152. Pulmonary Disease Aerosol Delivery Devices Industry Drivers Table 153. Pulmonary Disease Aerosol Delivery Devices Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pulmonary Disease Aerosol Delivery Devices Product Image Figure 5. Global Pulmonary Disease Aerosol Delivery Devices Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Pulmonary Disease Aerosol Delivery Devices Market Size (2021-2032) & (US$ Million) Figure 7. Global Pulmonary Disease Aerosol Delivery Devices Sales (2021-2032) & (K Units) Figure 8. Global Pulmonary Disease Aerosol Delivery Devices Average Price (US$/Unit) & (2021-2032) Figure 9. Metered- dose Inhalers Product Image Figure 10. Dry-powder Inhalers Product Image Figure 11. Nebulizers Product Image Figure 12. Asthma Product Image Figure 13. Idiopathic Pulmonary Fibrosis (IPF) Product Image Figure 14. Cystic Fibrosis (CF) Product Image Figure 15. Chronic Obstructive Pulmonary Disease (COPD) Product Image Figure 16. Others Product Image Figure 17. Global Pulmonary Disease Aerosol Delivery Devices Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Pulmonary Disease Aerosol Delivery Devices Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Pulmonary Disease Aerosol Delivery Devices Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Pulmonary Disease Aerosol Delivery Devices Sales by Region in 2025 Figure 23. Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region in 2025 Figure 24. North America Pulmonary Disease Aerosol Delivery Devices Market Size by Country in 2025 Figure 25. North America Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 26. North America Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Country (2021-2032) Figure 27. United States Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Pulmonary Disease Aerosol Delivery Devices Market Size by Country in 2025 Figure 31. Europe Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 32. Europe Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Country (2021-2032) Figure 33. Germany Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Market Size by Country in 2025 Figure 44. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Country (2021-2032) Figure 46. China Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Pulmonary Disease Aerosol Delivery Devices Market Size by Country in 2025 Figure 55. South America Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 56. South America Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Country (2021-2032) Figure 57. Brazil Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Market Size by Country in 2025 Figure 61. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Country (2021-2032) Figure 63. Egypt Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Pulmonary Disease Aerosol Delivery Devices Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2032) Figure 69. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2032) Figure 70. Global Pulmonary Disease Aerosol Delivery Devices Price (US$/Unit) by Type (2021-2032) Figure 71. Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2032) Figure 72. Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2032) Figure 73. Global Pulmonary Disease Aerosol Delivery Devices Price (US$/Unit) by Application (2021-2032) Figure 74. Pulmonary Disease Aerosol Delivery Devices Value Chain Figure 75. Pulmonary Disease Aerosol Delivery Devices Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges

Scope & coverage.

Types
  • Metered- dose Inhalers
  • Dry-powder Inhalers
  • Nebulizers
Applications
  • Asthma
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Cystic Fibrosis (CF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
Companies covered
  • Novartis
  • Merck
  • Viatris
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Vectura
  • Teva Pharmaceutical Industries
  • PARI International
  • OMRON
  • Monaghan Medical
  • Koninklijke Philips
  • H&T Presspart
  • Chiesi Farmaceutici
  • Boehringer Ingelheim
  • AptarGroup

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Pulmonary Disease Aerosol Delivery Devices Market Size (2021-2032)
  4. 2.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales (2021-2032)
  5. 2.2.3 Global Pulmonary Disease Aerosol Delivery Devices Market Average Price (2021-2032)
  6. 2.3 Pulmonary Disease Aerosol Delivery Devices by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Metered- dose Inhalers
  9. 2.3.3 Dry-powder Inhalers
  10. 2.3.4 Nebulizers
  11. 2.4 Pulmonary Disease Aerosol Delivery Devices by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Asthma
  14. 2.4.3 Idiopathic Pulmonary Fibrosis (IPF)
  15. 2.4.4 Cystic Fibrosis (CF)
  16. 2.4.5 Chronic Obstructive Pulmonary Disease (COPD)
  17. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Pulmonary Disease Aerosol Delivery Devices Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Pulmonary Disease Aerosol Delivery Devices Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Pulmonary Disease Aerosol Delivery Devices Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Pulmonary Disease Aerosol Delivery Devices Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Product Type & Application
  8. 3.8 Global Manufacturers of Pulmonary Disease Aerosol Delivery Devices, Established Date
  9. 3.9 Global Pulmonary Disease Aerosol Delivery Devices Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novartis
  2. 4.1.1 Novartis Company Information
  3. 4.1.2 Novartis Business Overview
  4. 4.1.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  6. 4.1.5 Novartis Recent Developments
  7. 4.2 Merck
  8. 4.2.1 Merck Company Information
  9. 4.2.2 Merck Business Overview
  10. 4.2.3 Merck Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Merck Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  12. 4.2.5 Merck Recent Developments
  13. 4.3 Viatris
  14. 4.3.1 Viatris Company Information
  15. 4.3.2 Viatris Business Overview
  16. 4.3.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  18. 4.3.5 Viatris Recent Developments
  19. 4.4 GlaxoSmithKline (GSK)
  20. 4.4.1 GlaxoSmithKline (GSK) Company Information
  21. 4.4.2 GlaxoSmithKline (GSK) Business Overview
  22. 4.4.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  24. 4.4.5 GlaxoSmithKline (GSK) Recent Developments
  25. 4.5 AstraZeneca
  26. 4.5.1 AstraZeneca Company Information
  27. 4.5.2 AstraZeneca Business Overview
  28. 4.5.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  30. 4.5.5 AstraZeneca Recent Developments
  31. 4.6 Vectura
  32. 4.6.1 Vectura Company Information
  33. 4.6.2 Vectura Business Overview
  34. 4.6.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  36. 4.6.5 Vectura Recent Developments
  37. 4.7 Teva Pharmaceutical Industries
  38. 4.7.1 Teva Pharmaceutical Industries Company Information
  39. 4.7.2 Teva Pharmaceutical Industries Business Overview
  40. 4.7.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  42. 4.7.5 Teva Pharmaceutical Industries Recent Developments
  43. 4.8 PARI International
  44. 4.8.1 PARI International Company Information
  45. 4.8.2 PARI International Business Overview
  46. 4.8.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  48. 4.8.5 PARI International Recent Developments
  49. 4.9 OMRON
  50. 4.9.1 OMRON Company Information
  51. 4.9.2 OMRON Business Overview
  52. 4.9.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  54. 4.9.5 OMRON Recent Developments
  55. 4.10 Monaghan Medical
  56. 4.10.1 Monaghan Medical Company Information
  57. 4.10.2 Monaghan Medical Business Overview
  58. 4.10.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  60. 4.10.5 Monaghan Medical Recent Developments
  61. 4.11 Koninklijke Philips
  62. 4.11.1 Koninklijke Philips Company Information
  63. 4.11.2 Koninklijke Philips Business Overview
  64. 4.11.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  66. 4.11.5 Koninklijke Philips Recent Developments
  67. 4.12 H&T Presspart
  68. 4.12.1 H&T Presspart Company Information
  69. 4.12.2 H&T Presspart Business Overview
  70. 4.12.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  72. 4.12.5 H&T Presspart Recent Developments
  73. 4.13 Chiesi Farmaceutici
  74. 4.13.1 Chiesi Farmaceutici Company Information
  75. 4.13.2 Chiesi Farmaceutici Business Overview
  76. 4.13.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  78. 4.13.5 Chiesi Farmaceutici Recent Developments
  79. 4.14 Boehringer Ingelheim
  80. 4.14.1 Boehringer Ingelheim Company Information
  81. 4.14.2 Boehringer Ingelheim Business Overview
  82. 4.14.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  84. 4.14.5 Boehringer Ingelheim Recent Developments
  85. 4.15 AptarGroup
  86. 4.15.1 AptarGroup Company Information
  87. 4.15.2 AptarGroup Business Overview
  88. 4.15.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolio
  90. 4.15.5 AptarGroup Recent Developments
5 Global Pulmonary Disease Aerosol Delivery Devices Market Scenario by Region
  1. 5.1 Global Pulmonary Disease Aerosol Delivery Devices Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021-2032
  3. 5.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2021-2026
  4. 5.2.2 Global Pulmonary Disease Aerosol Delivery Devices Sales by Region: 2027-2032
  5. 5.3 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region: 2021-2032
  6. 5.3.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region: 2021-2026
  7. 5.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Region: 2027-2032
  8. 5.4 North America Pulmonary Disease Aerosol Delivery Devices Market Facts & Figures by Country
  9. 5.4.1 North America Pulmonary Disease Aerosol Delivery Devices Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  11. 5.4.3 North America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Pulmonary Disease Aerosol Delivery Devices Market Facts & Figures by Country
  16. 5.5.1 Europe Pulmonary Disease Aerosol Delivery Devices Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  18. 5.5.3 Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Pulmonary Disease Aerosol Delivery Devices Market Facts & Figures by Country
  41. 5.7.1 South America Pulmonary Disease Aerosol Delivery Devices Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  43. 5.7.3 South America Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2032)
  2. 6.1.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2021-2032)
  4. 6.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Type (2021-2032)
  5. 6.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Pulmonary Disease Aerosol Delivery Devices Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2032)
  2. 7.1.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Application (2021-2032)
  4. 7.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Application (2021-2032)
  5. 7.2.1 Global Pulmonary Disease Aerosol Delivery Devices Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Pulmonary Disease Aerosol Delivery Devices Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Pulmonary Disease Aerosol Delivery Devices Value Chain Analysis
  2. 8.1.1 Pulmonary Disease Aerosol Delivery Devices Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Pulmonary Disease Aerosol Delivery Devices Production Mode & Process
  5. 8.2 Pulmonary Disease Aerosol Delivery Devices Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Pulmonary Disease Aerosol Delivery Devices Distributors
  8. 8.2.3 Pulmonary Disease Aerosol Delivery Devices Customers
9 Global Pulmonary Disease Aerosol Delivery Devices Analyzing Market Dynamics
  1. 9.1 Pulmonary Disease Aerosol Delivery Devices Industry Trends
  2. 9.2 Pulmonary Disease Aerosol Delivery Devices Industry Drivers
  3. 9.3 Pulmonary Disease Aerosol Delivery Devices Industry Opportunities and Challenges
  4. 9.4 Pulmonary Disease Aerosol Delivery Devices Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst